205 related articles for article (PubMed ID: 36949279)
1. Can Immune Therapy Cure Acute Myeloid Leukemia?
Gale RP
Curr Treat Options Oncol; 2023 May; 24(5):381-386. PubMed ID: 36949279
[TBL] [Abstract][Full Text] [Related]
2. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
[TBL] [Abstract][Full Text] [Related]
3. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
4. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
5. How close are we to CAR T-cell therapy for AML?
Gill SI
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
[TBL] [Abstract][Full Text] [Related]
6. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
[TBL] [Abstract][Full Text] [Related]
7. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
8. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in CAR-T cell therapy for acute myeloid leukaemia.
Gao C; Li X; Xu Y; Zhang T; Zhu H; Yao D
J Cell Mol Med; 2024 May; 28(9):e18369. PubMed ID: 38712978
[TBL] [Abstract][Full Text] [Related]
11. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
13. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
15. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
17. Emerging Immunotherapy for Acute Myeloid Leukemia.
Tabata R; Chi S; Yuda J; Minami Y
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
Gu B; Chu J; Wu D
Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
[TBL] [Abstract][Full Text] [Related]
20. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
